Halozyme Therapeutics (HALO) Accumulated Expenses (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Accumulated Expenses data on file, last reported at $140.4 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 7.72% year-over-year to $140.4 million in Q1 2026; TTM through Mar 2026 was $140.4 million, a 7.72% increase from a year earlier, with the FY2025 full-year figure at $156.2 million, up 21.22% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $140.4 million, down from $156.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for HALO reached as high as $156.2 million in Q4 2025 and fell as low as $19.1 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $104.3 million across 5 years, with a median of $105.4 million in 2023.
• Across the five-year window, Accumulated Expenses jumped 336.34% in 2022 and declined 1.98% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $99.8 million in 2022, then advanced by 0.92% to $100.7 million in 2023, then advanced by 27.98% to $128.9 million in 2024, then grew by 21.22% to $156.2 million in 2025, then retreated by 10.13% to $140.4 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $140.4 million in Q1 2026, $156.2 million in Q4 2025, and $111.2 million in Q3 2025.